News ArticleBiocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon secures landmark 10-year biosimilar Pertuzumab partnership in Brazil; EBITDA at Rs 865 crore and net profit at Rs 41 crore for the quarter ending September 30, 2026
Biocon Limited reported consolidated total income of Rs 4,423 crore for Q2 FY27, with biopharma revenues rising 5% year-on-year to Rs 3,583 crore. The company achieved an EBITDA of Rs 865 crore and net profit of Rs 41 crore. A landmark 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at approximately USD 400 million was secured, supporting long-term growth.
Biocon Limited
General / Other
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Consolidated operating revenue for Q2 FY27 grew 2% to Rs 4,389 crore compared to the same period last year. The biopharma segment drove growth with a 5% year-on-year increase, driven by biosimilars revenue rising 3% to Rs 2,809 crore and generics revenue increasing 10% to Rs 774 crore.
The services business posted a sequential growth of 13% over the previous quarter, reaching Rs 833 crore. Interest cost decreased 12% year-on-year to Rs 240 crore due to balance sheet strengthening measures.
Biocon achieved a landmark 10-year biosimilar Pertuzumab partnership in Brazil valued around USD 400 million, supporting adoption in the country’s public oncology sector. Additionally, the company reached global patent settlements enabling early licensed launch dates for biosimilar Pertuzumab across key markets including Europe, UK, and the U.S.
In North America, Biocon captured market share for their biosimilar Ustekinumab (Yesintek®) and commercialized Yesafili™ as an interchangeable biosimilar aflibercept. Regulatory approvals were secured for the Yesintek® autoinjector in the U.S. and Canada.
In Europe, the company received a positive CHMP opinion for biosimilar Pertuzumab under the EMA’s new tailored clinical development pathway and MHRA approval in the UK for the insulin glargine facility in Malaysia. Emerging markets saw 13 product launches and regulatory approvals across APAC, LATAM, AFMET, and CIS regions.
Highlights
- Consolidated total income at Rs 4,423 crore for Q2 FY27, a 1% year-on-year increase.
- Biopharma revenue grew 5% year-on-year to Rs 3,583 crore, with biosimilars and generics contributing Rs 2,809 crore and Rs 774 crore respectively.
- Services segment revenue rose 13% sequentially to Rs 833 crore.
- EBITDA stood at Rs 865 crore; net profit was Rs 41 crore for the quarter.
- Interest expense reduced 12% year-on-year to Rs 240 crore.
- Secured a 10-year biosimilar Pertuzumab partnership in Brazil valued at ~USD 400 million supporting public oncology adoption.
Key Data Snapshot
What happened
- Biocon reported consolidated total income of Rs 4,423 crore for Q2 FY27, a 1% increase year-on-year.
- Biopharma revenue grew 5% year-on-year to Rs 3,583 crore, led by biosimilars and generics segments.
- The company recorded an EBITDA of Rs 865 crore and net profit of Rs 41 crore for the quarter.
- Interest costs decreased 12% year-on-year to Rs 240 crore following balance sheet strengthening measures.
- The company secured a landmark 10-year biosimilar Pertuzumab PDP partnership in Brazil worth approximately USD 400 million.
Key details
- Biosimilars revenue was Rs 2,809 crore, up 3% year-on-year; generics revenue increased 10% to Rs 774 crore.
- Services revenue grew 13% sequentially to Rs 833 crore in Q2 FY27.
- Global patent settlement with Genentech enables earliest licensed launches of biosimilar Pertuzumab in Europe, UK, U.S., and emerging markets.
- Regulatory approvals secured for Yesintek® autoinjector in North America and positive CHMP opinion in Europe for biosimilar Pertuzumab.
- Malaysia manufacturing facility’s second insulin glargine fill-finish line commenced commercial supply, supporting U.S. demand.
Business impact
- Pertuzumab partnership in Brazil supports long-term oncology treatment adoption via the public health network.
- Expanded global manufacturing capabilities and regulatory approvals position Biocon for strategic growth in biosimilars and insulin.
- Syngene, a Biocon group company, achieved 13% sequential revenue growth supported by contract development and manufacturing operations (CDMO) business.
- Early market launches of Yesafili™ and Yesintek® in the U.S. contributing to growth momentum.
- Awards and recognitions received for R&D excellence and employer ranking underline Biocon’s industry standing.
Regulatory and governance context
- Pertuzumab biosimilar received positive CHMP opinion under EMA’s new tailored clinical development approach.
- MHRA (UK) approved Biocon’s insulin glargine fill-finish line facility in Malaysia, expanding regulatory footprint.
- Global settlement with Genentech secured cleared launch timelines for biosimilar Pertuzumab across key regulated markets.
Highlights
- Consolidated total income at Rs 4,423 crore for Q2 FY27, a 1% year-on-year increase.
- Biopharma revenue grew 5% year-on-year to Rs 3,583 crore, with biosimilars and generics contributing Rs 2,809 crore and Rs 774 crore respectively.
- Services segment revenue rose 13% sequentially to Rs 833 crore.
- EBITDA stood at Rs 865 crore; net profit was Rs 41 crore for the quarter.
- Interest expense reduced 12% year-on-year to Rs 240 crore.
- Secured a 10-year biosimilar Pertuzumab partnership in Brazil valued at ~USD 400 million supporting public oncology adoption.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
Aegis Logistics Ltd. Confirms No Undisclosed Price Sensitive Information Amid Rising Equity Trading Volume
In response to a BSE inquiry on November 4, 2026, Aegis Logistics Ltd. clarified that the recent surge in trading volume of its equity shares is market-driven and based on investor interest tied to the company's performance and prospects. The company confirmed that it is in full compliance with SEBI (LODR) Regulations, 2015, and that no unpublished price sensitive information is pending disclosure.
Read Full Story
